Belite Bio to Participate in the 2025 Maxim Growth Summit

Core Insights - Belite Bio Inc is a clinical-stage drug development company focused on novel therapeutics for degenerative retinal diseases with significant unmet medical needs [2] Group 1: Company Overview - Belite Bio is targeting diseases such as STGD1 and GA in advanced dry AMD, as well as specific metabolic diseases [2] - The lead candidate, Tinlarebant, is an oral therapy aimed at reducing bisretinoid toxin accumulation in the eye [2] - Tinlarebant is currently undergoing multiple clinical trials, including a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) for adolescent STGD1 subjects, and a Phase 3 study (PHOENIX) for subjects with GA [2] Group 2: Upcoming Events - The executive management team will participate in the Maxim Growth Summit on October 22, 2025 [1] - Interested parties can schedule one-on-one meetings with management through their Maxim representative [1]